BioAtla and GATC Health announced a special purpose vehicle (SPV) transaction worth $40 million to advance ozuriftamab vedotin (Oz‑V; CAB‑ROR2‑ADC) into a registrational Phase 3 study for second‑line and later oropharyngeal squamous cell carcinoma (OPSCC). The financing structure is intended to underwrite the costs of a pivotal trial and accelerate development timelines. BioAtla’s CAB (conditionally active biologic) approach aims to increase tumor selectivity; the Phase 3 is designed to test Oz‑V in a registrational setting after earlier clinical data. The SPV model signals creative deal‑making to de‑risk registrational commitments and align investors on near‑term clinical milestones. Regulatory reviewers and potential partners will focus on trial design, patient selection, and biomarker strategies to support efficacy readouts and a potential submission for approval if the Phase 3 is positive.